Search Results for "Effective KOL Engagement"

Forbes Books Press Release Official

New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures

Sep 8^th • 5 mins read

Tom Caravela

Mastering the First Impression

Jan 28^th • 2 mins read

Tom Caravela

Interview Differentiator-Be a Story Teller

Mar 21^st • 1 min read

Tom Caravela

“Extreme Interviewing” – MSL Interview Tips and Insights from Medical Affairs Leaders

Jul 8^th • 1 min read

Tom Caravela

Job Search Checklist for Aspiring Medical Science Liaisons

May 16^th • 2 mins read

Tom Caravela

MSL Retention – What Matters Most

Mar 14^th • 2 mins read

Tom Caravela

MSL Hiring and Recruitment: 5 Ways to Support Diversity and Inclusion

May 18^th • 2 mins read

Tom Caravela

10 Ways to Make an Impact on a Phone Interview

Apr 8^th • 1 min read

Tom Caravela

Resume Writing and Editing Tips for Pharma Professionals

Aug 7^th • 1 min read

Bridget Rasmusson

6 Tips to Ace Your Next MSL Interview!

Sep 27^th • 1 min read

Bridget Rasmusson

Presentation Nails and Fails: 7 Tips to Ace Your Next MSL Presentation

Oct 11^th • 1 min read

Tom Caravela

INTENTION: The Key to Achieving Your Goals

Jan 20^th • 1 min read

Tom Caravela

MSL Evolution: New Trends and Titles That May Emerge

Apr 4^th • 1 min read

Tom Caravela

MSL People Skills: Top 10 Tips for Better Engagement

Apr 19^th • 8 mins read

Tom Caravela

Promotability: How to Land Your Next Promotion

May 4^th • 10 mins read

Bridget Rasmusson

Positioning Yourself to Become an MSL in 2022

Dec 20^th • 10 mins read

iNIZIO

Virtual Oncology MSL Team Increases KOL Engagement by 120%

Sep 2^nd • 1 min read

iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

May 15^th • 5 mins read

Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Apr 6^th • 12 mins read

Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Feb 22^nd • 8 mins read

Navigation

Results for 'Effective KOL Engagement'

New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures

Mastering the First Impression

Interview Differentiator-Be a Story Teller

“Extreme Interviewing” – MSL Interview Tips and Insights from Medical Affairs Leaders

Job Search Checklist for Aspiring Medical Science Liaisons

MSL Retention – What Matters Most

MSL Hiring and Recruitment: 5 Ways to Support Diversity and Inclusion

10 Ways to Make an Impact on a Phone Interview

Resume Writing and Editing Tips for Pharma Professionals

6 Tips to Ace Your Next MSL Interview!

Presentation Nails and Fails: 7 Tips to Ace Your Next MSL Presentation

INTENTION: The Key to Achieving Your Goals

MSL Evolution: New Trends and Titles That May Emerge

MSL People Skills: Top 10 Tips for Better Engagement

Promotability: How to Land Your Next Promotion

Positioning Yourself to Become an MSL in 2022

Virtual Oncology MSL Team Increases KOL Engagement by 120%

Transforming oncology: Five frontiers driving progress in cancer care

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Related Topics